How should a heparin allergy be managed, including treatment of reactions and alternative anticoagulation options?

Management of Heparin Allergy

If you suspect heparin allergy, immediately stop all heparin products and initiate alternative anticoagulation with argatroban, bivalirudin, danaparoid, fondaparinux, or direct oral anticoagulants (DOACs) at therapeutic doses while awaiting diagnostic confirmation. 1

Distinguish Between True Allergy and Heparin-Induced Thrombocytopenia (HIT)

The term "heparin allergy" encompasses two distinct entities requiring different management:

Heparin-Induced Thrombocytopenia (HIT)

• Most critical concern - immune-mediated prothrombotic condition, not a true allergy
• Calculate 4Ts score immediately to assess pre-test probability 2
• If 4Ts score ≥4 (intermediate/high probability): stop heparin immediately and start non-heparin anticoagulant at therapeutic doses without waiting for lab results 1, 2
• If 4Ts score ≤3 (low probability): HIT unlikely, continue heparin, no need for HIT testing 2
• Monitor platelet count - HIT typically causes ≥50% drop or platelets <100,000/mm³ occurring 5-10 days after heparin exposure 3
• Key warning: Skin necrosis at injection sites suggests HIT with thrombosis, not simple hypersensitivity 1

True Hypersensitivity Reactions

• Delayed-type (Type IV): Most common (96% of true allergies) - itchy, inflammatory plaques at subcutaneous injection sites appearing hours to days later 4, 5
• Immediate-type (IgE-mediated): Extremely rare (4% of cases) - anaphylaxis within 5-10 minutes of injection 4, 6

Alternative Anticoagulation Options

For Acute HIT (Confirmed or High Suspicion)

First-line choices depend on clinical context:

Stable Patients (No Severe Organ Dysfunction, Low Bleeding Risk)

Fondaparinux or DOACs are preferred due to simplicity - no monitoring required 1

• Fondaparinux: Standard dosing, half-life ~17 hours
• Rivaroxaban: Most studied DOAC for HIT - 15mg twice daily initially, then 20mg daily for ≥1 month 1

Unstable/ICU Patients or High Bleeding Risk

Argatroban or bivalirudin preferred due to short half-lives allowing rapid reversal 1

• Argatroban:

  • Initial dose 1 mcg/kg/min (reduce to 0.5 mcg/kg/min in ICU, cardiac surgery, or Child-Pugh B liver disease) 1
  • Monitor with aPTT (target 2-3× control) or preferably diluted thrombin time (target 0.5-1.5 mg/mL) 1
  • Half-life ~50 minutes 1

• Bivalirudin:

  • Half-life 20-30 minutes 1
  • Preferred if severe hepatic impairment (Child-Pugh C) 1

Severe Renal Failure (CrCl <30 mL/min)

Argatroban is the only option - does not accumulate in renal failure 1

• Danaparoid contraindicated (long half-life, renal elimination) 1

Danaparoid Sodium

• Curative IV dosing: Weight-based bolus (1250-3750 U) followed by infusion (400 U/h initially, adjust to anti-Xa 0.5-0.8 U/mL) 1
• Prophylactic doses are ineffective for acute HIT 1
• Half-life ~24 hours (anti-Xa activity) 1

For True Hypersensitivity Reactions (Non-HIT)

Delayed-Type Reactions (Subcutaneous Injection Site Reactions)

• Fondaparinux is the preferred alternative - only 6.3% cross-reactivity with heparin 4
• Critical finding: Intravenous UFH is tolerated despite positive intradermal testing to subcutaneous heparin 4
• If emergency IV anticoagulation needed: UFH can be given intravenously without allergy testing 4
• Broad cross-reactivity exists between UFH and all LMWHs (nadroparin, dalteparin, enoxaparin) - avoid switching between these 4

Immediate-Type Reactions (Anaphylaxis)

• Absolute contraindication to all heparins 6
• Alternatives: Fondaparinux, DOACs, hirudins (lepirudin if available), or direct thrombin inhibitors 6, 7
• These have completely different molecular structures from heparin polysaccharides 6

Critical Management Pitfalls

What NOT to Do in Acute HIT

• Never give platelet transfusions unless life-threatening bleeding 1
• Never start warfarin/VKA alone - causes venous gangrene and skin necrosis; only add when platelets >150,000/mm³ as supplement to parenteral anticoagulant 1
• Never use antiplatelet agents to treat acute HIT 1
• Do not place IVC filters 1
• Do not use prophylactic doses of alternative anticoagulants - therapeutic doses required even without thrombosis 1

Surgical Considerations

• Postpone elective surgery ≥1 month after HIT diagnosis if possible 1
• For urgent surgery in acute HIT (<1 month):
  • Stop oral anticoagulants, bridge with argatroban or bivalirudin 1
  • Stop argatroban 4 hours pre-op, bivalirudin 2 hours pre-op 1
  • Danaparoid/fondaparinux require >36 hours pre-op due to long half-lives 1

Cardiac Surgery with Cardiopulmonary Bypass

• Check anti-PF4 antibodies (ELISA) before any cardiac surgery in patients with HIT history 1
• If antibodies undetectable: short-term UFH exposure acceptable intraoperatively 1
• If antibodies present: use bivalirudin, argatroban, or IV antiplatelet agent (tirofiban/cangrelor) + UFH 1

Long-Term Management

• Continue therapeutic anticoagulation ≥1 month minimum, even without thrombosis 1
• Transition to oral anticoagulant (VKA or DOAC) or fondaparinux for long-term therapy once platelets >150,000/mm³ 1
• Provide patient card documenting HIT diagnosis, lab results, and heparin exclusion 1
• Haemostasis consultation within 3 months of diagnosis 1

Special Populations

Pregnancy: Danaparoid first-line (does not cross placenta); fondaparinux second-line; argatroban and DOACs contraindicated 1

Pediatrics: Danaparoid or argatroban can be used with careful dose adjustment and monitoring 1